Presenting Author: Sarah R. Hoffman, PhD, MS, MPH (she/her/hers) – Carelon Research
### she/her/hers @@@ Francesca Kolitsopoulos, MPH – Pfizer, Inc., New York, NY, USA ### 1358445###Co-Author######Pfizer, Inc., New York, NY, USA###Co-Author: Francesca Kolitsopoulos, MPH – Pfizer, Inc., New York, NY, USA
### @@@ Aziza Jamal-Allial, PhD, MS – Carelon Research ### 1062683###Co-Author###Research Scientist of Epidemiology###Carelon Research###Co-Author: Aziza Jamal-Allial, PhD, MS – Carelon Research
### @@@ Keith Wilner – Pfizer ### 1659545###Co-Author######Pfizer###Co-Author: Keith Wilner – Pfizer
### @@@ Cynthia Senerchia, RN, MS – Optum ### 1658028###Co-Author###Vice President###Optum###Co-Author: Cynthia Senerchia, RN, MS – Optum
### @@@ Daina Esposito, MPH, PhD (she/her/hers) – Moderna, Inc. ### 1655290###Co-Author###Sr. Director, Global Safety Epidemiologist###Moderna, Inc.###Co-Author: Daina Esposito, MPH, PhD (she/her/hers) – Moderna, Inc.
### she/her/hers @@@ James Harnett, PharmD, MS – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1655631###Co-Author######Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: James Harnett, PharmD, MS – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
###Presenting Author: Shahab Abtahi, MD, PhD – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### @@@ Romin Pajouheshnia, PhD – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University ### 1063167###Co-Author###Assistant Professor (formerly)###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University###Co-Author: Romin Pajouheshnia, PhD – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### @@@ Carlos E. Durán, MD, PhD – Julius Global Health, University Medical Center Utrecht ### 1655741###Co-Author###Postdoctoral researcher###Julius Global Health, University Medical Center Utrecht###Co-Author: Carlos E. Durán, MD, PhD – Julius Global Health, University Medical Center Utrecht
### @@@ Judit Riera-Arnau, MD – Department of Datascience and Biostatistics, Julius Centrum, University Medical Center of Utrecht (UMCU), The Netherlands ### 1991418###Co-Author###PhD candidate###Department of Datascience and Biostatistics, Julius Centrum, University Medical Center of Utrecht (UMCU), The Netherlands###Co-Author: Judit Riera-Arnau, MD – Department of Datascience and Biostatistics, Julius Centrum, University Medical Center of Utrecht (UMCU), The Netherlands
### @@@ Miriam C. Sturkenboom, PhD – Department of Biostatistics and Research support, Julius Center for Health sciences and Primary care, University Medical Center Utrecht, the Netherlands ### 1359696###Co-Author###Professor###Department of Biostatistics and Research support, Julius Center for Health sciences and Primary care, University Medical Center Utrecht, the Netherlands###Co-Author: Miriam C. Sturkenboom, PhD – Department of Biostatistics and Research support, Julius Center for Health sciences and Primary care, University Medical Center Utrecht, the Netherlands
### @@@ Olaf H. Klungel, PharmD, PhD – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University ### 1062523###Co-Author###Professor###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University###Co-Author: Olaf H. Klungel, PharmD, PhD – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
###Presenting Author: Anthony Chen, BSc, MSc (he/him/his) – University of Nottingham
### he/him/his @@@ Chengsheng Ju, MPharm (he/him/his) – Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom ### 1991171###Co-Author###PhD Researcher###Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom###Co-Author: Chengsheng Ju, MPharm (he/him/his) – Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom
### he/him/his @@@ Isla S. Mackenzie, PhD – University of Dundee ### 1991526###Co-Author###Professor###University of Dundee###Co-Author: Isla S. Mackenzie, PhD – University of Dundee
### @@@ Allan D. Struthers, MD – University of Dundee ### 1991527###Co-Author###Professor###University of Dundee###Co-Author: Allan D. Struthers, MD – University of Dundee
### @@@ Li Wei, MBChB, MSc, MPH, PhD – Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom ### 1358231###Co-Author###Professor###Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom###Co-Author: Li Wei, MBChB, MSc, MPH, PhD – Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom
### @@@ Kenneth KC Man, MPH, PhD, FRSPH (he/him/his) – UCL School of Pharmacy, University College London, London, United Kingdom ### 1358158###Co-Author###Lecturer in Pharmacoepidemiology and Medication Safety###UCL School of Pharmacy, University College London, London, United Kingdom###Co-Author: Kenneth KC Man, MPH, PhD, FRSPH (he/him/his) – UCL School of Pharmacy, University College London, London, United Kingdom
### he/him/hisPresenting Author: Kyle Johnson, MSc – Mcgill University Department of Epidemiology, Biostatistics, and Occupational Health
### @@@ Sarah Beradid – Lady Davis Institute ### 1991427###Co-Author######Lady Davis Institute###Co-Author: Sarah Beradid – Lady Davis Institute
### @@@ James M. Brophy, MD, PhD – McGill University ### 1359484###Co-Author######McGill University###Co-Author: James M. Brophy, MD, PhD – McGill University
### @@@ Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada ### 1358167###Co-Author###Professor###Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada###Co-Author: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
### he/him/his @@@ Christel Renoux, MD PhD – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada ### 1358292###Co-Author###Associate Professor###Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada###Co-Author: Christel Renoux, MD PhD – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
###Presenting Author: Jesse M. van den Berg, MD (he/him/his) – PHARMO Institute for Drug Outcomes Research
### he/him/his @@@ Marieke T. Blom, PhD – Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of General Practice ### 1659198###Co-Author######Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of General Practice###Co-Author: Marieke T. Blom, PhD – Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of General Practice
### @@@ Karin M.A Swart, PhD – PHARMO Institute for Drug Outcomes Research ### 1358327###Co-Author###Senior Researcher###PHARMO Institute for Drug Outcomes Research###Co-Author: Karin M.A Swart, PhD – PHARMO Institute for Drug Outcomes Research
### @@@ Jetty A. Overbeek, PhD – PHARMO Institute for Drug Outcomes Research ### 1062554###Co-Author###Head of PHARMO Research###PHARMO Institute for Drug Outcomes Research###Co-Author: Jetty A. Overbeek, PhD – PHARMO Institute for Drug Outcomes Research
### @@@ Sharon Remmelzwaal – Amsterdam UMC location Vrije Universiteit Amsterdam, department of General Practice ### 1991363###Co-Author######Amsterdam UMC location Vrije Universiteit Amsterdam, department of General Practice###Co-Author: Sharon Remmelzwaal – Amsterdam UMC location Vrije Universiteit Amsterdam, department of General Practice
### @@@ Petra JM Elders, MD PhD – dpt of General Practice, Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of General Practice ### 1360375###Co-Author###Professor of General Practice###dpt of General Practice, Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of General Practice###Co-Author: Petra JM Elders, MD PhD – dpt of General Practice, Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of General Practice
### @@@ Ron M.C. Herings, PharmD,PhD – PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands ### 1657462###Co-Author###Professor in Pharmaco-epidemiology and Healthcare Optimization, Director of the PHARMO Institute###PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands###Co-Author: Ron M.C. Herings, PharmD,PhD – PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands
###Presenting Author: Katherine Callaway Kim, MPH – Department of Medicine, Division of General Internal Medicine, University of Pittsburgh School of MedicineDepartment of Health Policy and Management, University of Pittsburgh School of Public Health
### @@@ Scott D. Rothenberger, PhD – Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA ### 1358097###Co-Author###Assistant Professor###Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA###Co-Author: Scott D. Rothenberger, PhD – Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
### @@@ Mina Tadrous, PharmD, PhD, MS, FISPE – University of Toronto ### 1062862###Co-Author###Assistant Professor###University of Toronto###Co-Author: Mina Tadrous, PharmD, PhD, MS, FISPE – University of Toronto
### @@@ Inmaculada Hernandez, PharmD, PhD – Division of Clinical Pharmacy, University of California San Diego ### 1658462###Co-Author###Associate Professor###Division of Clinical Pharmacy, University of California San Diego###Co-Author: Inmaculada Hernandez, PharmD, PhD – Division of Clinical Pharmacy, University of California San Diego
### @@@ Walid Gellad, MD MPH – Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine ### 1358100###Co-Author###Professor of Medicine###Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine###Co-Author: Walid Gellad, MD MPH – Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine
### @@@ Lisa Maillart, PhD – Department of Industrial Engineering, University of Pittsburgh Swanson School of Engineering ### 1991464###Co-Author###Professor###Department of Industrial Engineering, University of Pittsburgh Swanson School of Engineering###Co-Author: Lisa Maillart, PhD – Department of Industrial Engineering, University of Pittsburgh Swanson School of Engineering
### @@@ Katie Suda, PharmD, M.S., FCCP (she/her/hers) – University of Pittsburgh ### 1360024###Co-Author###Professor###University of Pittsburgh###Co-Author: Katie Suda, PharmD, M.S., FCCP (she/her/hers) – University of Pittsburgh
### she/her/hersPresenting Author: Xi Xiong, Msc – The University of Hong Kong
### @@@ David Tak Wai Lui – University of Hong Kong ### 1993248###Co-Author######University of Hong Kong###Co-Author: David Tak Wai Lui – University of Hong Kong
### @@@ Matthew Shing Hin Chung – University of Hong Kong ### 1993249###Co-Author######University of Hong Kong###Co-Author: Matthew Shing Hin Chung – University of Hong Kong
### @@@ Ivan Chi Ho Au – University of Hong Kong ### 1993250###Co-Author######University of Hong Kong###Co-Author: Ivan Chi Ho Au – University of Hong Kong
### @@@ Francisco Tsz Tsun Lai – University of Hong Kong ### 1657436###Co-Author######University of Hong Kong###Co-Author: Francisco Tsz Tsun Lai – University of Hong Kong
### @@@ Eric Yuk Fai Wan – The University of Hong Kong ### 1358937###Co-Author######The University of Hong Kong###Co-Author: Eric Yuk Fai Wan – The University of Hong Kong
### @@@ Celine Sze Ling Chui, PhD – University of Hong Kong ### 1093237###Co-Author###Assistant Professor###University of Hong Kong###Co-Author: Celine Sze Ling Chui, PhD – University of Hong Kong
### @@@ Xue Li, PhD – The University of Hong Kong ### 1358457###Co-Author###Assistant Professor###The University of Hong Kong###Co-Author: Xue Li, PhD – The University of Hong Kong
### @@@ Franco Wing Tak Cheng – The University of Hong Kong ### 1991863###Co-Author######The University of Hong Kong###Co-Author: Franco Wing Tak Cheng – The University of Hong Kong
### @@@ Ching‐Lung Cheung, PhD (he/him/his) – University of Hong Kong ### 1358271###Co-Author###Associate Professor###University of Hong Kong###Co-Author: Ching‐Lung Cheung, PhD (he/him/his) – University of Hong Kong
### he/him/his @@@ Esther Wai Yin Chan – The University of Hong Kong ### 1358455###Co-Author######The University of Hong Kong###Co-Author: Esther Wai Yin Chan – The University of Hong Kong
### @@@ Chi Ho Lee – University of Hong Kong ### 1993251###Co-Author######University of Hong Kong###Co-Author: Chi Ho Lee – University of Hong Kong
### @@@ Yu Cho Woo – University of Hong Kong ### 1993252###Co-Author######University of Hong Kong###Co-Author: Yu Cho Woo – University of Hong Kong
### @@@ Kathryn Choon Beng Tan – University of Hong Kong ### 1993253###Co-Author######University of Hong Kong###Co-Author: Kathryn Choon Beng Tan – University of Hong Kong
### @@@ Carlos King Ho K. Wong – University of Hong Kong ### 1358585###Co-Author######University of Hong Kong###Co-Author: Carlos King Ho K. Wong – University of Hong Kong
### @@@ Ian Chi Kei Wong, PhD (he/him/his) – The University of Hong Kong ### 1358232###Co-Author###Head of Department of Pharmacology and Pharmacy###The University of Hong Kong###Co-Author: Ian Chi Kei Wong, PhD (he/him/his) – The University of Hong Kong
### he/him/hisPresenting Author: Wenzhen Ge, PhD (she/her/hers) – Regeneron Pharmaceuticals
### she/her/hers @@@ Alexi Archambault, PhD, MPH – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1658114###Co-Author###Sr. Manager, Pharmacoepidemiology###Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: Alexi Archambault, PhD, MPH – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### @@@ Thomas E. Delea – Policy Analysis Inc (PAI), Cambridge, MA ### 1991467###Co-Author######Policy Analysis Inc (PAI), Cambridge, MA###Co-Author: Thomas E. Delea – Policy Analysis Inc (PAI), Cambridge, MA
### @@@ Karen Rodriguez Lorenc – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1658117###Co-Author######Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: Karen Rodriguez Lorenc – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### @@@ James Harnett, PharmD, MS – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1655631###Co-Author######Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: James Harnett, PharmD, MS – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### @@@ Aaron P. Moynahan, Masters degree – Policy Analysis Inc (PAI), Cambridge, MA ### 1991468###Co-Author###Senior programmer analyist###Policy Analysis Inc (PAI), Cambridge, MA###Co-Author: Aaron P. Moynahan, Masters degree – Policy Analysis Inc (PAI), Cambridge, MA
### @@@ Derek Weycker, Ph.D. – Policy Analysis Inc (PAI), Cambridge, MA ### 1991469###Co-Author######Policy Analysis Inc (PAI), Cambridge, MA###Co-Author: Derek Weycker, Ph.D. – Policy Analysis Inc (PAI), Cambridge, MA
### @@@ Yariv Houvras – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1991470###Co-Author######Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: Yariv Houvras – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### @@@ Glenn S. Kroog, MD – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1658118###Co-Author###Executive Director###Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: Glenn S. Kroog, MD – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### @@@ Ning Wu, PhD – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1360274###Co-Author###Director of Health Economics and Outcomes Research###Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: Ning Wu, PhD – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### @@@ Christian Hampp, PhD, FISPE (he/him/his) – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1360408###Co-Author###Director, Pharmacoepidemiology###Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: Christian Hampp, PhD, FISPE (he/him/his) – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### he/him/his @@@ Qiufei Ma – Regeneron Pharmaceuticals, Inc., Tarrytown, NY ### 1991471###Co-Author######Regeneron Pharmaceuticals, Inc., Tarrytown, NY###Co-Author: Qiufei Ma – Regeneron Pharmaceuticals, Inc., Tarrytown, NY
### @@@ Sikander Ailawadhi – Mayo Clinic ### 1991472###Co-Author######Mayo Clinic###Co-Author: Sikander Ailawadhi – Mayo Clinic
###Presenting Author: Loreen Straub, MD MS – Brigham and Women's Hospital/Harvard Medical School
### @@@ Brian T. Bateman, MD, MSc – Department of Anesthesiology, Perioperative and Pain Medicine, Department of Epidemiology and Population Health, Stanford University School of Medicine ### 1088175###Co-Author######Department of Anesthesiology, Perioperative and Pain Medicine, Department of Epidemiology and Population Health, Stanford University School of Medicine###Co-Author: Brian T. Bateman, MD, MSc – Department of Anesthesiology, Perioperative and Pain Medicine, Department of Epidemiology and Population Health, Stanford University School of Medicine
### @@@ Krista F. Huybrechts, MS, PhD, FISPE – Brigham and Women's Hospital, Harvard Medical School ### 1359931###Co-Author######Brigham and Women's Hospital, Harvard Medical School###Co-Author: Krista F. Huybrechts, MS, PhD, FISPE – Brigham and Women's Hospital, Harvard Medical School
### @@@ Seanna Vine – Brigham and Women's Hospital ### 1397958###Co-Author######Brigham and Women's Hospital###Co-Author: Seanna Vine – Brigham and Women's Hospital
###Presenting Author: Wajd Alkabbani, MSc – University of Waterloo
### @@@ Colleen J. Maxwell, PhD – University of Waterloo ### 1655899###Co-Author###Professor###University of Waterloo###Co-Author: Colleen J. Maxwell, PhD – University of Waterloo
### @@@ Ruth Ann Marrie, MD, PhD – University of Manitoba ### 1358111###Co-Author######University of Manitoba###Co-Author: Ruth Ann Marrie, MD, PhD – University of Manitoba
### @@@ Suzanne Tyas – University of Waterloo ### 1655900###Co-Author######University of Waterloo###Co-Author: Suzanne Tyas – University of Waterloo
### @@@ Iliana Lega – University of Toronto ### 1655357###Co-Author######University of Toronto###Co-Author: Iliana Lega – University of Toronto
### @@@ John-Michael Gamble, PhD – University of Waterloo ### 1302773###Co-Author###Clinical Associate Professor; Associate Director, Graduate Studies and Research###University of Waterloo###Co-Author: John-Michael Gamble, PhD – University of Waterloo
###Presenting Author: Hamid Mahmoudpour, PharmD, PhD (he/him/his) – Global Epidemiology, the healthcare business of Merck KGaA, Darmstadt, Germany
### he/him/his @@@ Craig Knott – Health Data Insight CIC; NHS Digital, Leeds, UK ### 1991494###Co-Author######Health Data Insight CIC; NHS Digital, Leeds, UK###Co-Author: Craig Knott – Health Data Insight CIC; NHS Digital, Leeds, UK
### @@@ Amerah Amin – Health Outcomes, Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA ### 1658449###Co-Author######Health Outcomes, Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA###Co-Author: Amerah Amin – Health Outcomes, Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA
### @@@ Emmanuelle Boutmy, Msc, PhD – Global Epidemiology, the healthcare business of Merck KGaA, Darmstadt, Germany ### 1360043###Co-Author###Associate Director Biostatistics###Global Epidemiology, the healthcare business of Merck KGaA, Darmstadt, Germany###Co-Author: Emmanuelle Boutmy, Msc, PhD – Global Epidemiology, the healthcare business of Merck KGaA, Darmstadt, Germany
### @@@ Patrice Verpillat, MD, MPH, PhD – European Medicines Agency ### 1409656###Co-Author###Head of Real World Evidence###European Medicines Agency###Co-Author: Patrice Verpillat, MD, MPH, PhD – European Medicines Agency
###Lead Speaker: Rishi J. Desai, PhD – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
### @@@ Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University ### 1046831###Speaker###Professor and Director###Center for Pharmacoepidemiology and Treatment Science, Rutgers University###Speaker: Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University
### he/him/his @@@ Jodi B. Segal, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine ### 1302718###Speaker###Professor###Johns Hopkins University School of Medicine###Speaker: Jodi B. Segal, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine
### she/her/hers @@@ Madhav Thambisetty, MD, PhD – Clinical and Translational Neuroscience Section, National Institute on Aging, National Institutes of Health ### 1991535###Speaker######Clinical and Translational Neuroscience Section, National Institute on Aging, National Institutes of Health###Speaker: Madhav Thambisetty, MD, PhD – Clinical and Translational Neuroscience Section, National Institute on Aging, National Institutes of Health
###Lead Speaker: Jennifer Gerber, PhD, MSc – GlaxoSmithKline
### @@@ Morgan Marks, PhD (he/him/his) – Infectious Disease Epidemiology, Moderna Therapeutics Inc. ### 1359188###Speaker###Senior Director###Infectious Disease Epidemiology, Moderna Therapeutics Inc.###Speaker: Morgan Marks, PhD (he/him/his) – Infectious Disease Epidemiology, Moderna Therapeutics Inc.
### he/him/his @@@ Henok Tadesse Ayele, PhD – Merck & Co., Inc. ### 1062670###Speaker###Pricnicipal Scientist###Merck & Co., Inc.###Speaker: Henok Tadesse Ayele, PhD – Merck & Co., Inc.
### @@@ Hector S. Izurieta, MD, MPH, PhD – Office of Vaccines Research and Review, CBER/FDA ### 1659297###Speaker###Associate Director ###Office of Vaccines Research and Review, CBER/FDA###Speaker: Hector S. Izurieta, MD, MPH, PhD – Office of Vaccines Research and Review, CBER/FDA
### @@@ Robert T. Chen, MA, MD, FISPE – Brighton Collaboration ### 1088150###Speaker###Scientific Director###Brighton Collaboration###Speaker: Robert T. Chen, MA, MD, FISPE – Brighton Collaboration
### @@@ Joanne Wu, ScD (she/her/hers) – Pfizer Inc ### 1993416###Speaker###Associate Director, Epidemiology###Pfizer Inc###Speaker: Joanne Wu, ScD (she/her/hers) – Pfizer Inc
### she/her/hers @@@ Cindy Ke Zhou, PhD, MBBS (she/her/hers) – Moderna, Inc ### 1991413###Speaker###Director, Global Safety Epidemiology###Moderna, Inc###Speaker: Cindy Ke Zhou, PhD, MBBS (she/her/hers) – Moderna, Inc
### she/her/hers @@@ Deshayne B. Fell – University of Ottawa ### 1062677###Speaker###Dr. ###University of Ottawa###Speaker: Deshayne B. Fell – University of Ottawa
### @@@ Annette Regan, PhD, MPH (she/her/hers) – University of San Francisco, San Francisco CA, USA ### 1655874###Speaker###Associate Professor###University of San Francisco, San Francisco CA, USA###Speaker: Annette Regan, PhD, MPH (she/her/hers) – University of San Francisco, San Francisco CA, USA
### she/her/hers @@@ Leah J. McGrath, PhD – Pfizer ### 1659611###Speaker###Senior Director, Vaccines RWE###Pfizer###Speaker: Leah J. McGrath, PhD – Pfizer
### @@@ Christopher G. Prener, PhD – Pfizer, Inc ### 1991415###Speaker###Director, Vaccines RWE Biocurator Scientist###Pfizer, Inc###Speaker: Christopher G. Prener, PhD – Pfizer, Inc
###Lead Speaker: Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health
### she/her/hers @@@ Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1062592###Speaker###Associate Professor###Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill###Speaker: Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### she/her/hers @@@ Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC ### 1088164###Speaker###Assistant Professor###Department of Population Health Sciences, Duke University School of Medicine, Durham, NC###Speaker: Sudha R. Raman, PhD (she/her/hers) – Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
### she/her/hers @@@ Mugdha Gokhale, PhD – Pfizer ### 1088166###Speaker###Director, Value & Evidence###Pfizer###Speaker: Mugdha Gokhale, PhD – Pfizer
### @@@ Til Stürmer, MD, PhD (he/him/his) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1062525###Speaker###Professor###Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill###Speaker: Til Stürmer, MD, PhD (he/him/his) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### he/him/his @@@ Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet ### 1932107###Speaker###Postdoctoral Researcher###Karolinska Institutet###Speaker: Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet
### she/her/hersCo-Author: Marina G. Birck, Pharmacist, MSc, PhD (she/her/hers) – Research Institute of the McGill University Health Centre
### she/her/hers @@@ Autumn Neville – Research Institute of the McGill University Health Centre ### 1991323###Co-Author######Research Institute of the McGill University Health Centre###Co-Author: Autumn Neville – Research Institute of the McGill University Health Centre
### @@@ Louise Pilote, MD, MPH, PhD, FRCPC – Research Institute of the McGill University Health Centre ### 1360026###Co-Author######Research Institute of the McGill University Health Centre###Co-Author: Louise Pilote, MD, MPH, PhD, FRCPC – Research Institute of the McGill University Health Centre
### @@@ Erik Youngson, Mr, MMath, P.Stat – Alberta Strategy for Patient Oriented Research ### 1991324###Co-Author###Associate Director###Alberta Strategy for Patient Oriented Research###Co-Author: Erik Youngson, Mr, MMath, P.Stat – Alberta Strategy for Patient Oriented Research
### @@@ James A. King – Alberta Strategy for Patient Oriented Research ### 1991325###Co-Author######Alberta Strategy for Patient Oriented Research###Co-Author: James A. King – Alberta Strategy for Patient Oriented Research
### @@@ Anick Bérard, PhD, FISPE (she/her/hers) – University of Montreal ### 1302804###Co-Author###Professor Researcher###University of Montreal###Co-Author: Anick Bérard, PhD, FISPE (she/her/hers) – University of Montreal
### she/her/hers @@@ Sherif Eltonsy, PhD – University of Manitoba ### 1357974###Co-Author###Assistant Professor###University of Manitoba###Co-Author: Sherif Eltonsy, PhD – University of Manitoba
### @@@ Cristiano S. Moura – Research Institute of the McGill University Health Centre ### 1062600###Co-Author######Research Institute of the McGill University Health Centre###Co-Author: Cristiano S. Moura – Research Institute of the McGill University Health Centre
### @@@ Sasha Bernatsky, MD, PhD – McGill University, Dept. of Medicine and CORE ### 1358207###Presenting Author###Professor of medicine ###McGill University, Dept. of Medicine and CORE###Presenting Author: Sasha Bernatsky, MD, PhD – McGill University, Dept. of Medicine and CORE
###Co-Author: Wilhelmine Meeraus, PhD – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK
### @@@ Christen M. Gray – Real World Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK ### 1360359###Co-Author######Real World Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK###Co-Author: Christen M. Gray – Real World Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
### @@@ Eduardo Conde-Sousa – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK ### 1991345###Co-Author######Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK###Co-Author: Eduardo Conde-Sousa – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK
### @@@ Andrew Lee – Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Cambridge, UK ### 1991346###Co-Author######Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Cambridge, UK###Co-Author: Andrew Lee – Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Cambridge, UK
### @@@ Abigail Postema – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK ### 1991347###Co-Author######Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK###Co-Author: Abigail Postema – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK
### @@@ Andre Santa Maria – Evidence Generation, AstraZeneca, São Paulo, Brazil ### 1991348###Co-Author######Evidence Generation, AstraZeneca, São Paulo, Brazil###Co-Author: Andre Santa Maria – Evidence Generation, AstraZeneca, São Paulo, Brazil
### @@@ Bárbara Emoingt Furtado, MD, MBA – Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, São Paulo, Brazil ### 1991349###Co-Author###International Associate Medical Director Vaccines & Immune###Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, São Paulo, Brazil###Co-Author: Bárbara Emoingt Furtado, MD, MBA – Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, São Paulo, Brazil
### @@@ Claudia Corte – Evidence Generation, AstraZeneca, São Paulo, Brazil ### 1991350###Co-Author######Evidence Generation, AstraZeneca, São Paulo, Brazil###Co-Author: Claudia Corte – Evidence Generation, AstraZeneca, São Paulo, Brazil
### @@@ Mario Ouwens, PhD – Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Mölndal, Sweden ### 1358658###Co-Author######Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Mölndal, Sweden###Co-Author: Mario Ouwens, PhD – Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Mölndal, Sweden
### @@@ Sylvia Taylor, PhD, MPH, MBA – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK ### 1658805###Presenting Author###Senior Director, Epidemiology###Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK###Presenting Author: Sylvia Taylor, PhD, MPH, MBA – Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK
###Lead Speaker: Judith C. Maro, PhD (she/her/hers) – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School
### she/her/hers @@@ Tarry Ahuja, PhD (he/him/his) – Canadian Agency for Drugs and Technologies in Health ### 1991598###Speaker###Director, Post-Market Drug Evaluation###Canadian Agency for Drugs and Technologies in Health###Speaker: Tarry Ahuja, PhD (he/him/his) – Canadian Agency for Drugs and Technologies in Health
### he/him/his @@@ Melissa Kampman, PhD (she/her/hers) – Health Canada ### 1991542###Speaker###Manager, Data Analytics and Real-world Evidence Division###Health Canada###Speaker: Melissa Kampman, PhD (she/her/hers) – Health Canada
### she/her/hers @@@ David Moeny, MPH (he/him/his) – U.S. Food and Drug Administration ### 1655443###Speaker###Acting Deputy Director, Office of Pharmacovigilance and Epidemiology###U.S. Food and Drug Administration###Speaker: David Moeny, MPH (he/him/his) – U.S. Food and Drug Administration
### he/him/his @@@ Kristian B. Filion, PhD (he/him/his) – McGill University ### 1062622###Speaker###Associate Professor###McGill University###Speaker: Kristian B. Filion, PhD (he/him/his) – McGill University
### he/him/hisLead Speaker: Petra Denig, PharmD, PhD, FISPE – University Medical Center Groningen
### @@@ Lotte Rasmussen, MScPharm, PhD – Syddansk Universitet ### 1358115###Lead Speaker###Assistant professor###Syddansk Universitet###Lead Speaker: Lotte Rasmussen, MScPharm, PhD – Syddansk Universitet
### @@@ Mina Tadrous, PharmD, PhD, MS, FISPE – University of Toronto ### 1062862###Speaker###Assistant Professor###University of Toronto###Speaker: Mina Tadrous, PharmD, PhD, MS, FISPE – University of Toronto
### @@@ Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia ### 1655255###Speaker###Professor of Pharmacy###Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia###Speaker: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
### @@@ Björn Wettermark, MscPharm, PhD (he/him/his) – Uppsala university ### 1358174###Speaker###Professor###Uppsala university###Speaker: Björn Wettermark, MscPharm, PhD (he/him/his) – Uppsala university
### he/him/hisLead Speaker: Harriet Dickinson, MPhil, PhD – Gilead
### @@@ Dana Y. Teltsch, PhD, MSc – Takeda ### 1088160###Lead Speaker###Global Medical Evidence###Takeda###Lead Speaker: Dana Y. Teltsch, PhD, MSc – Takeda
### @@@ Victoria Y. Strauss, PhD – Boehringer Ingelheim Pharma GmbH & Co. KG ### 1088161###Speaker###Director TA Methodology Statistician RWE ###Boehringer Ingelheim Pharma GmbH & Co. KG###Speaker: Victoria Y. Strauss, PhD – Boehringer Ingelheim Pharma GmbH & Co. KG
### @@@ Orla M. Doyle, PhD, BEng – Novartis ### 1088162###Speaker###Director Data Science###Novartis###Speaker: Orla M. Doyle, PhD, BEng – Novartis
### @@@ Kathryn Rough, ScD, ScM (she/her/hers) – IQVIA ### 1653783###Speaker###Associate Director of Epidemiology###IQVIA###Speaker: Kathryn Rough, ScD, ScM (she/her/hers) – IQVIA
### she/her/hersCo-Author: Mallika L. Mundkur, MD, MPH – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration
### @@@ Monica A. Munoz, PharmD, PhD (she/her/hers) – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration ### 1358805###Co-Author###Director, Division of Pharmacovigilance I###Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration###Co-Author: Monica A. Munoz, PharmD, PhD (she/her/hers) – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration
### she/her/hers @@@ Qin Ryan, MD, PhD – Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration ### 1991373###Co-Author######Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration###Co-Author: Qin Ryan, MD, PhD – Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration
### @@@ Rosanna Setse, MD, PhD – Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration ### 1991374###Co-Author######Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration###Co-Author: Rosanna Setse, MD, PhD – Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration
### @@@ Sarah K. Dutcher, PhD, MS – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration ### 1360313###Co-Author###Epidemiologist###Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration###Co-Author: Sarah K. Dutcher, PhD, MS – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration
### @@@ José J. Hernández-Muñoz, PhD – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration ### 1991185###Presenting Author###Senior Pharmacist/Pharmacoepidemiologist###Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration###Presenting Author: José J. Hernández-Muñoz, PhD – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration
### @@@ Meredith Epperson – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School ### 1991460###Co-Author######Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School###Co-Author: Meredith Epperson – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School
### @@@ Laura Hou – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School ### 1359984###Co-Author###Research Analyst II###Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School###Co-Author: Laura Hou – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School
### @@@ James Marshall, MPH – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School ### 1358682###Co-Author###Research Analyst III###Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School###Co-Author: James Marshall, MPH – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School
### @@@ Elizabeth K. Sirasonian – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School ### 1657942###Co-Author######Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School###Co-Author: Elizabeth K. Sirasonian – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School
### @@@ Emma C. Whited – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School ### 1991461###Co-Author######Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School###Co-Author: Emma C. Whited – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School
### @@@ Michael D. Blum, MD – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration ### 1991375###Co-Author######Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration###Co-Author: Michael D. Blum, MD – Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration
### @@@ Judith C. Maro, PhD (she/her/hers) – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School ### 1062626###Co-Author###Assistant Professor###Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School###Co-Author: Judith C. Maro, PhD (she/her/hers) – Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School
### she/her/hersCo-Author: Thomas Delvin, MD – Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health,Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark
### @@@ Sofie D. Egsgaard, MSPH (she/her/hers) – University of Southern Denmark ### 1991402###Co-Author###PhD-Student###University of Southern Denmark###Co-Author: Sofie D. Egsgaard, MSPH (she/her/hers) – University of Southern Denmark
### she/her/hers @@@ Helene Kildegaard, MD – Clinical Pharmacology, Pharmacy and Environmental Medicine, Dept. of Puiblic Health, University of Southern Denmark ### 1358299###Co-Author###MD###Clinical Pharmacology, Pharmacy and Environmental Medicine, Dept. of Puiblic Health, University of Southern Denmark###Co-Author: Helene Kildegaard, MD – Clinical Pharmacology, Pharmacy and Environmental Medicine, Dept. of Puiblic Health, University of Southern Denmark
### @@@ Lars Christian Lund, PhD (he/him/his) – Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark. ### 1062545###Presenting Author###Postdoctoral researcher###Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark.###Presenting Author: Lars Christian Lund, PhD (he/him/his) – Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark.
### he/him/his @@@ Martin Torp Rahbek, MD – University of Southern Denmark/Department of Public Health ### 1991403###Co-Author######University of Southern Denmark/Department of Public Health###Co-Author: Martin Torp Rahbek, MD – University of Southern Denmark/Department of Public Health
###Presenting Author: Jenna Wong, PhD – Harvard Medical School & Harvard Pilgrim Health Care Institute
### @@@ Suzanne M. Bertisch, MD, MPH – Harvard Medical School & Brigham and Women's Hospital ### 1991681###Co-Author######Harvard Medical School & Brigham and Women's Hospital###Co-Author: Suzanne M. Bertisch, MD, MPH – Harvard Medical School & Brigham and Women's Hospital
### @@@ Darren Toh, ScD – Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA ### 1358101###Co-Author######Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA###Co-Author: Darren Toh, ScD – Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
###Co-Moderator: Susan dosReis, PhD – University of Maryland School of Pharmacy, Baltimore, Maryland, USA
### @@@ Daniel B. Horton, MD, MSCE, FISPE (he/him/his) – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA ### 1302719###Co-Moderator###Associate Professor of Pediatrics and Epidemiology###Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA###Co-Moderator: Daniel B. Horton, MD, MSCE, FISPE (he/him/his) – Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; Rutgers University, New Brunswick, NJ, USA
### he/him/his